ARV drug levels in CVF fall off rapidly following IVR removal (grey arrow) but are quantifiable for a further 2 wk. Every circular datum represents an individual sample from one of the participants (n = 6), while triangles depict samples that were BLQ of the analytical method, and values were calculated as follows: [(assay BLQ)/2]/(median swab mass). (A) TDF. (B) TFV. (C) Box plots of ARV drug terminal half-lives of elimination from CVF. The box extends from the 25th to 75th percentiles, with the horizontal line in the box representing the median; whiskers represent the lowest and highest datum. Comparison of the TDF and TFV groups using an unpaired t test with Welch’s correction showed that the groups were significantly different (P = 0.00...
1<p>Manually handled, gel expelled in trash, n = 2.</p>2<p>Unopened applicator, removed from foil pa...
Every circular datum represents an individual sample from one of the participants (n = 6); horizonta...
Trials of a vaginal Tenofovir gel for pre-exposure prophylaxis (PrEP) for HIV have given conflicting...
ARV drug levels in CVF fall off rapidly following IVR removal (grey arrow) but are quantifiable for ...
ARV drug levels in CVFs fall off rapidly following IVR removal (grey arrows) but are quantifiable fo...
(A) ARV drug and TFV-DP levels in vaginal biopsies collected on Day 7 within 30 min of pod-IVR remov...
(A) ARV drug and TFV-DP levels in vaginal biopsies collected on Day 7 within 30 min of pod-IVR remov...
(A) Chronic 251 cohort (n = 6) assessed. (B) Kinetics of plasma (red lines) and CSF (blue lines) vir...
<p>Blue, proximal to the IVR; red, distal to the IVR; each circle corresponds to an individual datum...
CVF, cervicovaginal fluid; VT, vaginal tissue; RF, rectal fluid. Measurements outside of the analyti...
CVF, cervicovaginal fluid; VT, vaginal tissue; RF, rectal fluid. Data consist of medians (interquart...
<p>Blue, Day 34 (<i>N</i> = 2); red, Day 35 (<i>N</i> = 2); and green, Day 36 (<i>N</i> = 2). The in...
§<p>Predicted compartment dose concentrations to suppress 50, 90 and 95% of HIV infection interpolat...
<p><b>(A) TFV in CV aspirate</b>. Blue Bars: TFV IVR, Red Bars: TFV/LNG IVR, Visit 4, pooled across ...
Trials of a vaginal Tenofovir gel for pre-exposure prophylaxis (PrEP) for HIV have given conflicting...
1<p>Manually handled, gel expelled in trash, n = 2.</p>2<p>Unopened applicator, removed from foil pa...
Every circular datum represents an individual sample from one of the participants (n = 6); horizonta...
Trials of a vaginal Tenofovir gel for pre-exposure prophylaxis (PrEP) for HIV have given conflicting...
ARV drug levels in CVF fall off rapidly following IVR removal (grey arrow) but are quantifiable for ...
ARV drug levels in CVFs fall off rapidly following IVR removal (grey arrows) but are quantifiable fo...
(A) ARV drug and TFV-DP levels in vaginal biopsies collected on Day 7 within 30 min of pod-IVR remov...
(A) ARV drug and TFV-DP levels in vaginal biopsies collected on Day 7 within 30 min of pod-IVR remov...
(A) Chronic 251 cohort (n = 6) assessed. (B) Kinetics of plasma (red lines) and CSF (blue lines) vir...
<p>Blue, proximal to the IVR; red, distal to the IVR; each circle corresponds to an individual datum...
CVF, cervicovaginal fluid; VT, vaginal tissue; RF, rectal fluid. Measurements outside of the analyti...
CVF, cervicovaginal fluid; VT, vaginal tissue; RF, rectal fluid. Data consist of medians (interquart...
<p>Blue, Day 34 (<i>N</i> = 2); red, Day 35 (<i>N</i> = 2); and green, Day 36 (<i>N</i> = 2). The in...
§<p>Predicted compartment dose concentrations to suppress 50, 90 and 95% of HIV infection interpolat...
<p><b>(A) TFV in CV aspirate</b>. Blue Bars: TFV IVR, Red Bars: TFV/LNG IVR, Visit 4, pooled across ...
Trials of a vaginal Tenofovir gel for pre-exposure prophylaxis (PrEP) for HIV have given conflicting...
1<p>Manually handled, gel expelled in trash, n = 2.</p>2<p>Unopened applicator, removed from foil pa...
Every circular datum represents an individual sample from one of the participants (n = 6); horizonta...
Trials of a vaginal Tenofovir gel for pre-exposure prophylaxis (PrEP) for HIV have given conflicting...